Therefore, the anti-PD-1 antibody pembrolizumab was administered to three cohorts, A, B, and C, respectively, comprising 25 CRC patients with MMR deletion, 25 CRC patients with normal MMR, and 21 patients with cancers other than CRC with MMR deletion. Here, PDCD1 is linked to colorectal carcinoma.